{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:47:32Z","timestamp":1792014452327,"version":"4.4.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100023452","name":"Hanarth Fonds","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023452","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The introduction of improved multi-agent systemic therapies has made restaging and treatment response assessment in patients with localized pancreatic ductal adenocarcinoma (PDAC) increasingly complex. This scoping review aims to assess and compare methods for local disease restaging and treatment response assessment in localized PDAC, with a focus on their association with resectability, overall survival (OS), and R0-resection rates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>This scoping review included studies on restaging in patients with PDAC following systemic therapy using CT and PET\/CT from MEDLINE, Embase, and CENTRAL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 4680 identified studies, 20 fulfilled the eligibility criteria. Most (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200915) studies analyzed CT, and 5 analyzed PET\/CT. Groups of restaging methods included new response categories, size-based metrics, volume, vascular contact, tumor attenuation, fluorine-18 fluorodeoxyglucose (\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG) PET\/CT derived metabolic parameters, and resectability criteria. Dual-energy CT-derived extracellular volume (DECT-ECV) was evaluated as a baseline predictive biomarker. Associations between restaging methods and outcomes were reported inconsistently: some studies found significant associations for specific methods, whereas others did not. No restaging method showed a consistent association with both R0-resection and survival across all studies.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Restaging of localized PDAC after systemic treatment remains challenging due to the limited accuracy of RECIST 1.1, particularly for the classifications partial response and stable disease. The current evidence suggests that integrating additional imaging features, alternative imaging modalities, and the biomarker carbohydrate antigen (CA)19-9 may improve the assessment of resectability and prognosis. These findings support a future version of RECIST 1.1 to alert clinicians to this issue.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key Points<\/jats:title>\n                    <jats:p>\n                      <jats:bold>\n                        <jats:italic>Question<\/jats:italic>\n                      <\/jats:bold>\n                      <jats:italic>How effective are current (PET\/)CT-based restaging methods in assessing local disease resectability and prognosis in localized PDAC after modern multi-agent systemic therapy?<\/jats:italic>\n                    <\/jats:p>\n                    <jats:p>\n                      <jats:bold>\n                        <jats:italic>Findings<\/jats:italic>\n                      <\/jats:bold>\n                      <jats:italic>Current restaging methods show inconsistent association with R0-resection and survival; RECIST 1.1 is particularly limited for the assessment of partial response and stable disease<\/jats:italic>\n                      .\n                    <\/jats:p>\n                    <jats:p>\n                      <jats:bold>\n                        <jats:italic>Clinical relevance<\/jats:italic>\n                      <\/jats:bold>\n                      <jats:italic>Current evidence confirms a need to integrate additional imaging features and the biomarker CA19-9, during restaging in patients with localized pancreatic cancer after modern systemic therapy to improve accuracy and reduce the risk of missed treatment options<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00330-026-12954-1","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T05:03:25Z","timestamp":1791867805000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Restaging the primary tumor in localized pancreatic ductal adenocarcinoma after systemic therapy: a scoping review of the role of CT, FDG-PET, and CA19-9"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-1794-5741","authenticated-orcid":false,"given":"A. M.","family":"Lamor\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. P. M.","family":"Kop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. A.","family":"Zamboni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Zins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. E.","family":"Revheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Malekzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Stoker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. A.","family":"Marquering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. G.","family":"Besselink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. M.","family":"Verpalen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,13]]},"reference":[{"key":"12954_CR1","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.mpmed.2024.02.009","volume":"52","author":"S Dilke","year":"2024","unstructured":"Dilke S, Spalding D (2024) Pancreatic cancer. Medicine 52:289\u2013295","journal-title":"Medicine"},{"key":"12954_CR2","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1200\/OP.22.00328","volume":"19","author":"Y Jiang","year":"2023","unstructured":"Jiang Y, Sohal DPS (2023) Pancreatic adenocarcinoma management. JCO Oncol Pract 19:19\u201332","journal-title":"JCO Oncol Pract"},{"key":"12954_CR3","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247","journal-title":"Eur J Cancer"},{"key":"12954_CR4","doi-asserted-by":"publisher","first-page":"5749","DOI":"10.1002\/cncr.27636","volume":"118","author":"MH Katz","year":"2012","unstructured":"Katz MH, Fleming JB, Bhosale P et al (2012) Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer 118:5749\u20135756","journal-title":"Cancer"},{"key":"12954_CR5","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s00261-017-1434-7","volume":"43","author":"V Baliyan","year":"2018","unstructured":"Baliyan V, Kordbacheh H, Parakh A, Kambadakone A (2018) Response assessment in pancreatic ductal adenocarcinoma: role of imaging. Abdom Radiol (NY) 43:435\u2013444","journal-title":"Abdom Radiol (NY)"},{"key":"12954_CR6","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1148\/radiol.2019190422","volume":"293","author":"I Joo","year":"2019","unstructured":"Joo I, Lee JM, Lee ES et al (2019) Preoperative CT classification of the resectability of pancreatic cancer: interobserver agreement. Radiology 293:343\u2013349","journal-title":"Radiology"},{"key":"12954_CR7","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s12149-021-01629-0","volume":"35","author":"L Evangelista","year":"2021","unstructured":"Evangelista L, Zucchetta P, Moletta L et al (2021) The role of FDG PET\/CT or PET\/MRI in assessing response to neoadjuvant therapy for patients with borderline or resectable pancreatic cancer: a systematic literature review. Ann Nucl Med 35:767\u2013776","journal-title":"Ann Nucl Med"},{"key":"12954_CR8","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/M18-0850","volume":"169","author":"AC Tricco","year":"2018","unstructured":"Tricco AC, Lillie E, Zarin W et al (2018) PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med 169:467\u2013473","journal-title":"Ann Intern Med"},{"key":"12954_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/nhs.12673","volume":"22","author":"C Lockwood","year":"2020","unstructured":"Lockwood C, Tricco AC (2020) Preparing scoping reviews for publication using methodological guides and reporting standards. Nurs Health Sci 22:1\u20134","journal-title":"Nurs Health Sci"},{"key":"12954_CR10","doi-asserted-by":"publisher","first-page":"5609","DOI":"10.1007\/s00261-021-03284-5","volume":"46","author":"Y Guo","year":"2021","unstructured":"Guo Y, Czeyda-Pommersheim F, Miccio JA, Mahalingam S, Cecchini M, Pahade J (2021) Can a simplified CT response criteria for vascular involvement in pancreatic adenocarcinoma after neoadjuvant therapy predict survival in patients who achieved subsequent R0 resection? Abdom Radiol (NY) 46:5609\u20135617","journal-title":"Abdom Radiol (NY)"},{"key":"12954_CR11","doi-asserted-by":"publisher","first-page":"887","DOI":"10.6004\/jnccn.2022.7018","volume":"20","author":"CA Hester","year":"2022","unstructured":"Hester CA, Perri G, Prakash LR et al (2022) Radiographic and serologic response to first-line chemotherapy in unresected localized pancreatic cancer. J Natl Compr Cancer Netw 20:887\u2013897","journal-title":"J Natl Compr Cancer Netw"},{"key":"12954_CR12","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.pan.2025.02.007","volume":"25","author":"SS Kim","year":"2025","unstructured":"Kim SS, Kim S, Jo JH et al (2025) Early response evaluation using CT and CA 19-9 in patients with pancreatic cancer of all stages undergoing first-line FOLFIRINOX treatment. Pancreatology 25:377\u2013384","journal-title":"Pancreatology"},{"key":"12954_CR13","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s00330-020-07188-8","volume":"31","author":"JK Jang","year":"2021","unstructured":"Jang JK, Byun JH, Kang JH et al (2021) CT-determined resectability of borderline resectable and unresectable pancreatic adenocarcinoma following FOLFIRINOX therapy. Eur Radiol 31:813\u2013823","journal-title":"Eur Radiol"},{"key":"12954_CR14","doi-asserted-by":"publisher","first-page":"3104","DOI":"10.1007\/s00330-016-4632-8","volume":"27","author":"M Wagner","year":"2017","unstructured":"Wagner M, Antunes C, Pietrasz D et al (2017) CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma. Eur Radiol 27:3104\u20133116","journal-title":"Eur Radiol"},{"key":"12954_CR15","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1177\/02841851261424497","volume":"67","author":"J Yoo","year":"2026","unstructured":"Yoo J, Park SJ, Kim H, Lee KB, Kim JH (2026) Prediction of tumor regression grade and identification of prognostic factors using CT and biological features in patients with pancreatic cancer who underwent surgery after neoadjuvant therapy. Acta Radiol 67:388\u2013398","journal-title":"Acta Radiol"},{"key":"12954_CR16","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1097\/SLA.0000000000003442","volume":"273","author":"G Perri","year":"2021","unstructured":"Perri G, Prakash L, Wang H et al (2021) Radiographic and serologic predictors of pathologic major response to preoperative therapy for pancreatic cancer. Ann Surg 273:806\u2013813","journal-title":"Ann Surg"},{"key":"12954_CR17","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1148\/radiol.14132914","volume":"273","author":"C Cassinotto","year":"2014","unstructured":"Cassinotto C, Mouries A, Lafourcade JP et al (2014) Locally advanced pancreatic adenocarcinoma: reassessment of response with CT after neoadjuvant chemotherapy and radiation therapy. Radiology 273:108\u2013116","journal-title":"Radiology"},{"key":"12954_CR18","doi-asserted-by":"publisher","first-page":"917","DOI":"10.3346\/jkms.2015.30.7.917","volume":"30","author":"WH Paik","year":"2015","unstructured":"Paik WH, Lee SH, Kim YT, Park JM, Song BJ, Ryu JK (2015) Objective assessment of surgical restaging after concurrent chemoradiation for locally advanced pancreatic cancer. J Korean Med Sci 30:917\u2013923","journal-title":"J Korean Med Sci"},{"key":"12954_CR19","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1007\/s00261-020-02605-4","volume":"46","author":"SA Ahmed","year":"2021","unstructured":"Ahmed SA, Mourad AF, Hassan RA et al (2021) Preoperative CT staging of borderline pancreatic cancer patients after neoadjuvant treatment: accuracy in the prediction of vascular invasion and resectability. Abdom Radiol (NY) 46:280\u2013289","journal-title":"Abdom Radiol (NY)"},{"key":"12954_CR20","doi-asserted-by":"publisher","first-page":"4265","DOI":"10.1007\/s00330-018-5410-6","volume":"28","author":"G Marchegiani","year":"2018","unstructured":"Marchegiani G, Todaro V, Boninsegna E et al (2018) Surgery after FOLFIRINOX treatment for locally advanced and borderline resectable pancreatic cancer: increase in tumour attenuation on CT correlates with R0 resection. Eur Radiol 28:4265\u20134273","journal-title":"Eur Radiol"},{"key":"12954_CR21","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1002\/ags3.12418","volume":"5","author":"H Akita","year":"2021","unstructured":"Akita H, Takahashi H, Eguchi H et al (2021) Difference between carbohydrate antigen 19-9 and fluorine-18 fluorodeoxyglucose positron emission tomography in evaluating the treatment efficacy of neoadjuvant treatment in patients with resectable and borderline resectable pancreatic ductal adenocarcinoma: results of a dual-center study. Ann Gastroenterol Surg 5:381\u2013389","journal-title":"Ann Gastroenterol Surg"},{"key":"12954_CR22","doi-asserted-by":"publisher","first-page":"199","DOI":"10.2967\/jnumed.121.261952","volume":"63","author":"MR Benz","year":"2022","unstructured":"Benz MR, Armstrong WR, Ceci F et al (2022) 18F-FDG PET\/CT imaging biomarkers for early and late evaluation of response to first-line chemotherapy in patients with pancreatic ductal adenocarcinoma. J Nucl Med 63:199\u2013204","journal-title":"J Nucl Med"},{"key":"12954_CR23","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1093\/bjs\/znab229","volume":"109","author":"W Lee","year":"2022","unstructured":"Lee W, Oh M, Kim JS et al (2022) Metabolic activity by FDG-PET\/CT after neoadjuvant chemotherapy in borderline resectable and locally advanced pancreatic cancer and association with survival. Br J Surg 109:61\u201370","journal-title":"Br J Surg"},{"key":"12954_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.suronc.2023.101909","volume":"47","author":"TL de Jong","year":"2023","unstructured":"de Jong TL, Koopman D, van der Worp CAJ et al (2023) Added value of digital FDG-PET\/CT in disease staging and restaging in patients with resectable or borderline resectable pancreatic cancer. Surg Oncol 47:101909","journal-title":"Surg Oncol"},{"key":"12954_CR25","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.6004\/jnccn.2022.7041","volume":"20","author":"AM Abdelrahman","year":"2022","unstructured":"Abdelrahman AM, Goenka AH, Alva-Ruiz R et al (2022) FDG-PET predicts neoadjuvant therapy response and survival in borderline resectable\/locally advanced pancreatic adenocarcinoma. J Natl Compr Canc Netw 20:1023\u20131032.e1023","journal-title":"J Natl Compr Canc Netw"},{"key":"12954_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2023.110834","volume":"163","author":"KV Guggenberger","year":"2023","unstructured":"Guggenberger KV, Bley TA, Held S et al (2023) Predictive value of computed tomography on surgical resectability in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicentre phase 2 trial (NEOLAP-AIO-PAK-0113). Eur J Radiol 163:110834","journal-title":"Eur J Radiol"},{"key":"12954_CR27","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/j.hpb.2023.06.015","volume":"25","author":"A Hayasaki","year":"2023","unstructured":"Hayasaki A, Mizuno S, Nagata M et al (2023) Extrapancreatic extension is a better adverse prognostic factor than tumor size in patients with localized pancreatic ductal adenocarcinoma treated with chemoradiotherapy\u2014comparison of T category between the American Joint Committee on Cancer and Japan Pancreas Society. HPB 25:1268\u20131277","journal-title":"HPB"},{"key":"12954_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2023.110756","volume":"162","author":"N Fujita","year":"2023","unstructured":"Fujita N, Ushijima Y, Itoyama M et al (2023) Extracellular volume fraction determined by dual-layer spectral detector CT: possible role in predicting the efficacy of preoperative neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma. Eur J Radiol 162:110756","journal-title":"Eur J Radiol"},{"key":"12954_CR29","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.hpb.2018.01.001","volume":"20","author":"E van Veldhuisen","year":"2018","unstructured":"van Veldhuisen E, Vogel JA, Klompmaker S et al (2018) Added value of CA19-9 response in predicting resectability of locally advanced pancreatic cancer following induction chemotherapy. HPB 20:605\u2013611","journal-title":"HPB"},{"key":"12954_CR30","doi-asserted-by":"publisher","first-page":"321.e1","DOI":"10.1016\/j.crad.2017.11.001","volume":"73","author":"JA Hwang","year":"2018","unstructured":"Hwang JA, Jang KM, Kim SH et al (2018) Integration of different criteria for borderline resectable pancreatic cancer using classification tree analysis: the use of radiological tumour-vascular interface in correlation with surgical and pathological outcomes. Clin Radiol 73:321.e1\u2013321","journal-title":"Clin Radiol"},{"key":"12954_CR31","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/archsurg.1992.01420110083017","volume":"127","author":"DB Evans","year":"1992","unstructured":"Evans DB, Rich TA, Byrd DR et al (1992) Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg 127:1335\u20131339","journal-title":"Arch Surg"},{"key":"12954_CR32","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.trecan.2022.08.005","volume":"8","author":"E Espinet","year":"2022","unstructured":"Espinet E, Klein L, Pure E, Singh SK (2022) Mechanisms of PDAC subtype heterogeneity and therapy response. Trends Cancer 8:1060\u20131071","journal-title":"Trends Cancer"},{"key":"12954_CR33","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s12149-023-01884-3","volume":"38","author":"S Watanabe","year":"2024","unstructured":"Watanabe S, Hirata K, Magota K et al (2024) Comparative study of physiological FDG uptake in small structures between silicon photomultiplier-based PET and conventional PET. Ann Nucl Med 38:131\u2013138","journal-title":"Ann Nucl Med"},{"key":"12954_CR34","doi-asserted-by":"publisher","first-page":"11S","DOI":"10.2967\/jnumed.108.057182","volume":"50","author":"R Boellaard","year":"2009","unstructured":"Boellaard R (2009) Standards for PET image acquisition and quantitative data analysis. J Nucl Med 50:11S\u201320S","journal-title":"J Nucl Med"},{"key":"12954_CR35","doi-asserted-by":"publisher","first-page":"122S","DOI":"10.2967\/jnumed.108.057307","volume":"50","author":"RL Wahl","year":"2009","unstructured":"Wahl RL, Jacene H, Kasamon Y, Lodge MA (2009) From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 50:122S\u2013150S","journal-title":"J Nucl Med"},{"key":"12954_CR36","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1002\/bjs.9892","volume":"102","author":"MD Chandrasegaram","year":"2015","unstructured":"Chandrasegaram MD, Goldstein D, Simes J et al (2015) Meta-analysis of radical resection rates and margin assessment in pancreatic cancer. Br J Surg 102:1459\u20131472","journal-title":"Br J Surg"},{"key":"12954_CR37","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jamcollsurg.2020.11.018","volume":"232","author":"RK Schmocker","year":"2021","unstructured":"Schmocker RK, Delitto D, Wright MJ et al (2021) Impact of margin status on survival in patients with pancreatic ductal adenocarcinoma receiving neoadjuvant chemotherapy. J Am Coll Surg 232:405\u2013413","journal-title":"J Am Coll Surg"},{"key":"12954_CR38","doi-asserted-by":"publisher","first-page":"6883","DOI":"10.1007\/s00330-023-09659-0","volume":"33","author":"A Jajodia","year":"2023","unstructured":"Jajodia A, Wang A, Alabousi M, Wilks C, Kulkarni A, van der Pol CB (2023) MRI vs. CT for pancreatic adenocarcinoma vascular invasion: comparative diagnostic test accuracy systematic review and meta-analysis. Eur Radiol 33:6883\u20136891","journal-title":"Eur Radiol"},{"key":"12954_CR39","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/j.annonc.2023.08.009","volume":"34","author":"T Conroy","year":"2023","unstructured":"Conroy T, Pfeiffer P, Vilgrain V et al (2023) Pancreatic cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 34:987\u20131002","journal-title":"Ann Oncol"},{"key":"12954_CR40","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.ejrad.2012.12.002","volume":"82","author":"C Cassinotto","year":"2013","unstructured":"Cassinotto C, Cortade J, Belleannee G et al (2013) An evaluation of the accuracy of CT when determining resectability of pancreatic head adenocarcinoma after neoadjuvant treatment. Eur J Radiol 82:589\u2013593","journal-title":"Eur J Radiol"},{"key":"12954_CR41","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1097\/SLA.0000000000000867","volume":"261","author":"CR Ferrone","year":"2015","unstructured":"Ferrone CR, Marchegiani G, Hong TS et al (2015) Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg 261:12\u201317","journal-title":"Ann Surg"},{"key":"12954_CR42","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.2169\/internalmedicine.0410-22","volume":"62","author":"K Kai","year":"2023","unstructured":"Kai K, Hiyoshi M, Imamura N et al (2023) A preliminary pathological evaluation of extracellular volume fraction with contrast-enhanced computed tomography as a novel quantitative parameter of pancreatic fibrosis. Intern Med 62:1107\u20131115","journal-title":"Intern Med"},{"key":"12954_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2023.111204","volume":"170","author":"S Sun","year":"2024","unstructured":"Sun S, Huang B, Li Q et al (2024) Prediction of pancreatic fibrosis by dual-energy CT-derived extracellular volume fraction: comparison with MRI. Eur J Radiol 170:111204","journal-title":"Eur J Radiol"},{"key":"12954_CR44","doi-asserted-by":"publisher","first-page":"4036","DOI":"10.1007\/s00259-023-06297-y","volume":"50","author":"J Ding","year":"2023","unstructured":"Ding J, Qiu J, Hao Z et al (2023) Comparing the clinical value of baseline [(68) Ga]Ga-FAPI-04 PET\/CT and [(18)F]F-FDG PET\/CT in pancreatic ductal adenocarcinoma: additional prognostic value of the distal pancreatitis. Eur J Nucl Med Mol Imaging 50:4036\u20134050","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"12954_CR45","doi-asserted-by":"publisher","first-page":"206","DOI":"10.2967\/jnumed.123.266283","volume":"65","author":"X Li","year":"2024","unstructured":"Li X, Lu N, Lin L et al (2024) 18)F-FAPI-04 outperforms (18)F-FDG PET\/CT in clinical assessments of patients with pancreatic adenocarcinoma. J Nucl Med 65:206\u2013212","journal-title":"J Nucl Med"},{"key":"12954_CR46","doi-asserted-by":"publisher","first-page":"4084","DOI":"10.7150\/thno.106108","volume":"15","author":"S Ruzzeh","year":"2025","unstructured":"Ruzzeh S, Abdlkadir AS, Paez D et al (2025) Therapeutic potential of FAPI RLT in oncology: a systematic review. Theranostics 15:4084\u20134100","journal-title":"Theranostics"}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-026-12954-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00330-026-12954-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-026-12954-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:02:06Z","timestamp":1792011726000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00330-026-12954-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,13]]},"references-count":46,"alternative-id":["12954"],"URL":"https:\/\/doi.org\/10.1007\/s00330-026-12954-1","relation":{},"ISSN":["1432-1084"],"issn-type":[{"value":"1432-1084","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,13]]},"assertion":[{"value":"1 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The scientific guarantor of this publication is Dr. I. M. Verpalen.","order":1,"name":"Ethics","label":"Guarantor","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"G.A.Z. is a deputy editor of European Radiology. J.S. is a member of the Advisory Editorial Board of European Radiology. As such, they did not participate in the selection or review processes for this article. The remaining authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.","order":2,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"No complex statistical methods were necessary for this paper.","order":3,"name":"Ethics","label":"Statistics and biometry","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Written informed consent was not required for this study because it was a scoping review.","order":4,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Institutional Review Board approval was not required because it was a scoping review.","order":5,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Not applicable for this paper since it was a scoping review.","order":6,"name":"Ethics","label":"Study subjects or cohorts overlap","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"order":7,"name":"Ethics","label":"Methodology","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}}]}}